The experts evaluated promising combination of optical and pharmaceutical treatments


HOYA Vision Care, a leader in optical technology innovation, today announced the outcome of a recently hosted virtual advisory meeting where five well-known experts in pediatric myopia discussed their opinions on combination treatment with atropine and optical inventions for myopia management. The advisory group, composed of key experts from Europe and Asia, including Prof. Hakan Kaymak, Internationale Innovative Ophthalmochirurgie, Duesseldorf, Germany, shared insights based on their clinical experience and research.

“The experts in the advisory meeting agreed that in order to prevent vision complications later in life, early detection, proper diagnostic measurement and treatment of myopia in children is critical,” said Pascal Blaser, Global Medical Affairs Manager Myopia at HOYA Vision Care. “We were pleased to be able to bring together this group of experts to facilitate discussions on the latest treatment options including the combination of optical and pharmaceutical treatments.”

The experts shared and discussed their experience with the MiYOSMART spectacle lens, including the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% atropine drops in European myopic children and adolescents when the expected goal using the spectacle lens was not achieved.

1 The experts noted a better control effect with the combination treatment. They reported no significant changes in visual acuity or binocular vision between the use of MiYOSMART spectacle lenses alone or in combination with low dosage atropine. These data shared by the experts, were recently presented at the International Myopia Conference held in Rotterdam, The Netherlands, along with research presented by Prof. Kaymak on his study of axial length growth under treatment with MiYOSMART spectacle lenses and atropine. A key outcome of the advisory meeting was the group reaching consensus on the use of the combination treatment combining HOYA’s MiYOSMART spectacle lenses and atropine drops for myopia management in children.

“The promising early treatment intervention I have seen in my work combining the MiYOSMART spectacle lens and atropine drops is a very exciting development as we continue to seek an evidence-based approach to myopia management in children,” said Prof. Kaymak, advisory member. “The consensus reached at HOYA’s advisory meeting on the combination treatment protocol helps eye care professionals make informed decisions in addressing the growing global challenge of myopia.”

Since its launch in 2018, MiYOSMART is available in more than 28 markets with over two million spectacle lenses purchased by parents around the world.

2 PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all
countries, including the U.S., and is not currently available for sale in all countries, including the U.S.
1 Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium ” New Insights to
Advance Myopia Management”: Axial length growth under therapy with MiYOSMART spectacle
lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple
Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is
influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated
Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC)
2022, September 4, Rotterdam, The Netherlands.
2Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.

# # #

About HOYA Vision Care
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology
innovation. As a manufacturer of high quality, high performing eyeglass lenses, HOYA continues to
drive optical technology innovation with the aim of finding the best vision care solutions for Eye Care
Professionals. The company supplies lenses in 52 countries with a network of over 18,000 employees
and 45 laboratories around the globe.

About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company
and a leading supplier of innovative high-tech and medical products. HOYA’s divisions and business
units research and develop products utilized in the healthcare and information technology fields. In
the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes,
contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device
reprocessing and disinfection solutions. In the information technology field, we provide products such
as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and
LCD/OLED devices, text to speech, human resources and other software solutions and critical
components for the mass memory and cloud storage industries. With over 150 offices and subsidiaries
worldwide, HOYA currently employs a multinational workforce of 37,000 people.